• Bone Morphogenetic Protein 4 Gene Therapy in Mice Inhibits Myeloma Tumor Growth, But Has a Negative Impact on Bone 

      Westhrin, Marita; Holien, Toril; Zahoor, Muhammad; Moen, Siv Helen; Buene, Glenn; Størdal, Berit Fladvad; Hella, Hanne; Yuan, Huipin; de Bruijn, Joost D; Martens, Anton; Groen, Richard WJ; Bosch, Fátima; Smith, Ulf; Sponaas, Anne-Marit; Sundan, Anders; Standal, Therese (Peer reviewed; Journal article, 2020)
      Multiple myeloma is characterized by accumulation of malignant plasma cells in the bone marrow. Most patients suffer from an osteolytic bone disease, caused by increased bone degradation and reduced bone formation. Bone ...
    • Bystander memory T cells and IMiD/checkpoint therapy in multiple myeloma: A dangerous tango? 

      Sponaas, Anne-Marit; Waage, Anders; Vandsemb, Esten; Misund, Kristine; Børset, Magne; Sundan, Anders; Slørdahl, Tobias Schmidt; Standal, Therese (Peer reviewed; Journal article, 2021)
      In this review article we discuss the role of the memory T cells in multiple myeloma (MM) and how they may influence immune responses in patients that received immunomodulating drugs and check point therapy
    • Caspase-8 regulates the expression of pro- and anti-inflammatory cytokines in human bone marrow-derived mesenchymal stromal cells 

      Moen, Siv Helen; Westhrin, Marita; Zahoor, Muhammad; Nikolai N., Nørgaard; Hella, Hanne; Størdal, Berit Fladvad; Sundan, Anders; Nilsen, Nadra J.; Sponaas, Anne-Marit; Standal, Therese (Journal article; Peer reviewed, 2016)
      Introduction: Mesenchymal stem cells, also called mesenchymal stromal cells, MSCs, have great potential in stem cell therapy partly due to their immunosuppressive properties. How these cells respond to chronic inflammatory ...
    • Checkpoint Inhibition in Multiple Myeloma 

      Yang, Rui (Doctoral theses at NTNU;2019:107, Doctoral thesis, 2019)
    • Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence 

      Misund, Kristine; Hofste op Bruinink, Davine; Coward, Eivind; Hoogenboezem, Remco M.; Rustad, Even Holth; Sanders, Mathijs A.; Rye, Morten Beck; Sponaas, Anne-Marit; van der Holt, Bronno; Zweegman, Sonja; Hovig, Eivind; Meza, Leonardo Zepeda; Sundan, Anders; Myklebost, Ola; Sonneveld, Pieter; Waage, Anders (Peer reviewed; Journal article, 2022)
      We investigated genomic and transcriptomic changes in paired tumor samples of 29 in-house multiple myeloma (MM) patients and 28 patients from the MMRF CoMMpass study before and after treatment. A change in clonal composition ...
    • Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade 

      Yang, Rui; Elsaadi, Samah; Misund, Kristine; Abdollahi, Pegah; Vandsemb, Esten; Moen, Siv Helen; Kusnierczyk, Anna; Slupphaug, Geir; Standal, Therese; Waage, Anders; Slørdahl, Tobias Schmidt; Rø, Torstein Baade; Rustad, Even Holth; Sundan, Anders; Hay, Carl; Cooper, Zachary; Schuller, Alwin G.; Woessner, Richard; Borodowski, Alexandra; Menu, Eline; Børset, Magne; Sponaas, Anne-Marit (Peer reviewed; Journal article, 2020)
      Background PD1/PDL1-directed therapies have been unsuccessful for multiple myeloma (MM), an incurable cancer of plasma cells in the bone marrow (BM). Therefore, other immune checkpoints such as extracellular adenosine and ...
    • Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non–small-cell Lung Cancer 

      Tøndell, Anders; Wahl, Sissel Gyrid Freim; Sponaas, Anne-Marit; Sørhaug, Sveinung; Børset, Magne; Haug, Markus (Journal article; Peer reviewed, 2019)
      Lung cancer is the leading cause of cancer death in both sexes worldwide and has a predicted 5-year survival rate of <20%. Immunotherapy targeting immune checkpoints such as the programmed death 1 (PD-1) signaling pathway ...
    • Flow analysis of RANK expression on myeloid cells and identification of bone marrow cells expressing IL-32 in multiple myeloma patients 

      Giliberto, Mariaserena (Master thesis, 2016)
      Multiple myeloma is the second most common hematological cancer worldwide, characterized by an increased expansion of malignant plasma cells in the bone marrow, organ dysfunction, immunodeficiency and bone erosion. Nearly ...
    • Highly expressed genes in multiple myeloma cells – what can they tell us about the disease? 

      Børset, Magne; Elsaadi, Samah; Vandsemb, Esten Nymoen; Hess, Eli Svorkdal; Steiro, Ida Johnsen; Cócera Fernández, Miguel; Sponaas, Anne-Marit; Abdollahi, Pegah (Peer reviewed; Journal article, 2022)
      Cancer cells can convert proto-oncoproteins into oncoproteins by increasing the expression of genes that are oncogenic when expressed at high levels. Such genes can promote oncogenesis without being mutated. To find ...
    • Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss 

      Zahoor, Muhammad; Westhrin, Marita; Aass, Kristin Roseth; Moen, Siv Helen; Misund, Kristine; Psonka-Antonczyk, Katarzyna Maria; Giliberto, Mariaserena; Buene, Glenn; Sundan, Anders; Waage, Anders; Sponaas, Anne-Marit; Standal, Therese (Journal article; Peer reviewed, 2017)
      Multiple myeloma (MM) is a hematologic cancer characterized by expansion of malignant plasma cells in the bone marrow. Most patients develop an osteolytic bone disease, largely caused by increased osteoclastogenesis. The ...
    • Intracellular IL-32 regulates mitochondrial metabolism, proliferation, and differentiation of malignant plasma cells 

      Aass, Kristin Roseth; Mjelle, Robin; Kastnes, Martin Haugrud; Tryggestad, Synne Stokke; van den Brink, Luca M; Roseth, Ingrid Aass; Westhrin, Marita; Zahoor, Muhammad; Moen, Siv Helen; Nedal, Tonje Marie Vikene; Buene, Glenn; Misund, Kristine; Sponaas, Anne-Marit; Ma, Qianli; Sundan, Anders; Groen, Richard WJ; Slørdahl, Tobias Schmidt; Waage, Anders; Standal, Therese (Journal article; Peer reviewed, 2021)
      Interleukin-32 (IL-32) is a nonclassical cytokine expressed in cancers, inflammatory diseases, and infections. Its expression is regulated by two different oxygen sensing systems; HIF1α and cysteamine dioxygenase (ADO), ...
    • Investigating the Role of PRL-3 and Targeting PHGDH in Multiple Myeloma 

      Elsaadi, Samah (Doctoral theses at NTNU;2020:378, Doctoral thesis, 2020)
      Myelomatose er en hematologisk kreftsykdom som skyldes klonal ekspansjon av plasmaceller som infiltrerer beinmargen. Til tross for fremskritt innen behandlingen av myelomatose, er sykdommen fortsatt uhelbredelig. Artiklene ...
    • PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy 

      Sponaas, Anne-Marit; Nejati Moharrami, Neda; Feyzi, Emadoldin; Standal, Therese; Rustad, Even Holth; Waage, Anders; Sundan, Anders (Peer reviewed; Journal article, 2015)
      In this study we set out to investigate whether anti PDL1 or PD–1 treatment targeting the immune system could be used against multiple myeloma. DCs are important in regulating T cell responses against tumors. We therefore ...
    • Phosphatase of Regenerating Liver-3 Regulates Cancer Cell Metabolism in Multiple Myeloma 

      Abdollahi, Pegah; Vandsemb, Esten; Elsaadi, Samah; Røst, Lisa Marie; Yang, Rui; Hjort, Magnus Aassved; Andreassen, Trygve; Misund, Kristine; Slørdahl, Tobias Schmidt; Rø, Torstein Baade; Sponaas, Anne-Marit; Moestue, Siver Andreas; Bruheim, Per; Børset, Magne (Peer reviewed; Journal article, 2021)
      Cancer cells often depend on microenvironment signals from molecules such as cytokines for proliferation and metabolic adaptations. PRL‐3, a cytokine‐induced oncogenic phosphatase, is highly expressed in multiple myeloma ...
    • PRL-3 induces a positive signaling circuit between glycolysis and activation of STAT1/2 

      Vandsemb, Esten; Rye, Morten Beck; Steiro, Ida Johnsen; Elsaadi, Samah; Rø, Torstein Baade; Slørdahl, Tobias Schmidt; Sponaas, Anne-Marit; Børset, Magne; Abdollahi, Pegah (Peer reviewed; Journal article, 2021)
      Multiple myeloma (MM) is an incurable hematologic malignancy resulting from the clonal expansion of plasma cells. MM cells are interacting with components of the bone marrow microenvironment such as cytokines to survive ...
    • Src family kinases are regulated in multiple myeloma cells by phosphatase of regenerating liver-3 

      Abdollahi, Pegah; Vandsemb, Esten Nymoen; Hjort, Magnus Aassved; Misund, Kristine; Holien, Toril; Sponaas, Anne-Marit; Rø, Torstein Baade; Slørdahl, Tobias Schmidt; Børset, Magne (Journal article; Peer reviewed, 2016)
      Phosphatase of regenerating liver-3 (PTP4A3/PRL-3) is a dual-specificity phosphatase that is upregulated in various types of cancers and is related to poor prognosis and aggressive tumor behavior. The expression level of ...
    • Targeting phosphoglycerate dehydrogenase in multiple myeloma 

      Elsaadi, Samah; Steiro, Ida Johnsen; Abdollahi, Pegah; Vandsemb, Esten; Yang, Rui; Slørdahl, Tobias Schmidt; Rø, Torstein Baade; Menu, Eline; Sponaas, Anne-Marit; Børset, Magne (Peer reviewed; Journal article, 2021)
      Background: Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of plasma cells in the bone marrow. To date, this disease is still incurable and novel therapeutic approaches are required. ...
    • The proportion of CD16+CD14dim monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma 

      Sponaas, Anne-Marit; Moen, Siv Helen; Liabakk, Nina-Beate; Feyzi, Emadoldin; Holien, Toril; Kvam, Solveig; Grøseth, Lill Anny Gunnes; Størdal, Berit Fladvad; Buene, Glenn; Espevik, Terje; Waage, Anders; Standal, Therese; Sundan, Anders (Journal article; Peer reviewed, 2015)
      Multiple myeloma is an incurable cancer with expansion of malignant plasma cells in the bone marrow. Previous studies have shown that monocytes and macrophages in the bone marrow milieu are important for tumor growth ...